Assenagon Asset Management S.A. Crinetics Pharmaceuticals, Inc. Transaction History
Assenagon Asset Management S.A.
- $65.1 Billion
- Q3 2025
A detailed history of Assenagon Asset Management S.A. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 12,338 shares of CRNX stock, worth $522,020. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,338Holding current value
$522,020% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CRNX
# of Institutions
237Shares Held
90.2MCall Options Held
59.7KPut Options Held
14.8K-
Vanguard Group Inc Valley Forge, PA9.26MShares$392 Million0.0% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.4MShares$271 Million1.78% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$264 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA5.81MShares$246 Million0.03% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.59MShares$237 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.27B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...